ACTL6A

Across TCGA pan-cancer cohorts, ACTL6A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACTL6A data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACTL6A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACTL6A expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where ACTL6A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.942	0.628	<.001	28	view →
UCEC	OS	Median	All	0.913	0.981	.030	6	view →
CCRCC	OS	Median	All	0.903	0.983	.023	2	view →
GBM	OS	Median	All	0.563	0.263	.011	2	view →
PDAC	OS	Tertile	II,III,IV	0.257	0.476	.041	1	view →
HNSC	OS	Tertile	IV	0.637	0.872	.023	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACTL6A–LUAD (OS)

Open the LUAD breakdown →